• 1. An auto-correction laser photoacoustic spectrometer based on 2f/1f wavelength modulation spectroscopy
  Ke Chen,Shuai Liu,Liang Mei,Feng Jin,Bo Zhang,Fengxiang Ma,Yewei Chen,Hong Deng,Min Guo,Qingxu Yu Analyst, 2020,145, 1524-1530
• 2. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219
• 3. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis
• 4. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 5. Aluminium coordination complexes in copolymerization reactions of carbon dioxide and epoxides
  Nduka Ikpo,Jenna C. Flogeras,Francesca M. Kerton Dalton Trans., 2013,42, 8998-9006

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Tetrahydroisoquinolines Tetrahydroisoquinolines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Tetrahydroisoquinolines
• Pharmaceutical and Biochemical Products Pharmaceutical Intermediates

Research Brief on 6-Methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol (CAS: 1011-42-3): Recent Advances and Applications

6-Methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol (CAS: 1011-42-3) is a tetrahydroisoquinoline derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. Recent studies have explored its pharmacological properties, synthetic pathways, and mechanisms of action, positioning it as a promising candidate for drug development. This research brief synthesizes the latest findings on this compound, highlighting its relevance in contemporary biomedical research.

The structural motif of tetrahydroisoquinoline is prevalent in numerous bioactive molecules, and 6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol is no exception. Recent investigations have focused on its role as a precursor or intermediate in the synthesis of more complex alkaloids with neuroprotective, antimicrobial, and anticancer activities. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in modulating dopamine receptors, suggesting potential applications in neurodegenerative disorders such as Parkinson's disease.

In terms of synthetic chemistry, advancements have been made in the efficient production of 6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol. A novel catalytic method utilizing palladium-based catalysts was reported in Organic Letters, achieving higher yields and reduced reaction times compared to traditional methods. This innovation is critical for scaling up production and facilitating further pharmacological studies. Additionally, the compound's stability and solubility profiles have been characterized, providing insights into its formulation potential.

Pharmacological studies have also revealed its antioxidant properties, as evidenced by its ability to scavenge free radicals in in vitro models. Research published in Bioorganic & Medicinal Chemistry Letters highlighted its protective effects against oxidative stress-induced cell damage, which could be leveraged in therapies for conditions like ischemia-reperfusion injury. Furthermore, preliminary in vivo studies in rodent models have shown promising results in reducing inflammation, opening avenues for its use in autoimmune diseases.

Despite these advancements, challenges remain in optimizing the bioavailability and selectivity of 6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol. Future research directions include structural modifications to enhance its pharmacokinetic properties and the exploration of its interactions with other biological targets. Collaborative efforts between chemists and biologists will be essential to translate these findings into clinical applications.

In conclusion, 6-methoxy-1,2,3,4-tetrahydroisoquinolin-7-ol (CAS: 1011-42-3) represents a versatile scaffold with significant potential in drug discovery. Its multifaceted pharmacological activities and improved synthetic accessibility underscore its value as a focal point for ongoing research. As the scientific community continues to unravel its mechanisms and applications, this compound is poised to make meaningful contributions to the development of novel therapeutics.

• 50896-90-7((R)-1-(3,4-Dimethoxybenzyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline)
• 4747-98-2((S)-Nor Laudanosine)
• 13074-31-2(1-(3,4-dimethoxyphenyl)methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline)
• 54417-53-7((R)-1,2,3,4-tetrahydro-6,7-dimethoxy-1-veratrylisoquinoline hydrochloride)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)